Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 02, 2022

BUY
$1.19 - $1.74 $160 - $234
135 New
135 $294,000
Q1 2020

Apr 28, 2020

SELL
$1.51 - $3.0 $2,515 - $4,998
-1,666 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$2.79 - $4.32 $4,648 - $7,197
1,666 New
1,666 $4,000

Others Institutions Holding GALT

About GALECTIN THERAPEUTICS INC


  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $123M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Capital Wealth Alliance, LLC Portfolio

Follow Capital Wealth Alliance, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Wealth Alliance, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Wealth Alliance, LLC with notifications on news.